The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|June 13, 2022
Rheumatoid Arthritis Quiz: Sex Differences in RA
Author(s)Ingrid Torjesen
Rheumatoid arthritis impacts men and women differently. How much do you know about the differences between the sexes? Take this quiz to find out.
Advertisement
What is the prevalence of rheumatoid arthritis in women when compared with men?
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement